Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 143NIH 72INDUSTRY 16NETWORK 13OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 71Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 54Prostatic Neoplasms 48Lung Neoplasms 48Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Immunoblastic Lymphadenopathy × Clear all
NCT02533700 2020-03-10

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Shandong Provincial Hospital

Phase 2 Unknown
106 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡